Drugs / BCX9930
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04330534 | Mar → Nov 2020 | paroxysmal nocturnal hemoglobinuria | BioCryst Pharmaceuticals | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT05741346 | Jan 2023 → Jan 2025 | paroxysmal nocturnal hemoglobinuria | BioCryst Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT05162066 | Feb → Sep 2022 | IgA glomerulonephritis, complement 3 glomerulopathy, membranous glomerulonephritis | BioCryst Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT05116774 | Dec 2021 → Sep 2023 | paroxysmal nocturnal hemoglobinuria | BioCryst Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT05116787 | Oct 2021 → Sep 2023 | paroxysmal nocturnal hemoglobinuria | BioCryst Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT04702568 | Dec 2020 → Oct 2023 | paroxysmal nocturnal hemoglobinuria | BioCryst Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCX9930 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05741346 ↗ |
| Route | Oral | “BCX9930 capsules for oral administration” NCT04330534 ↗ |